Mocertatug rezetecan plus immunotherapy as ongoing treatment for advanced or recurrent endometrial cancer
Tests mocertatug rezetecan added to immunotherapy in adults with advanced or recurrent endometrial cancer.
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Daegu, South KoreaSee the siteAlso in 2 other countries, 11 sites
- Trial code
- Registry title
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 610 people, planned
- Started
- 24 Sept 2026
- Expected to end
- 18 Sept 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mocertatug rezetecan
- Dostarlimab
- Pembrolizumab
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 or older with advanced or recurrent endometrial cancer. Their tumor must be mismatch repair proficient (MMRp) or microsatellite stable (MSS). They must have finished first-line chemotherapy with immunotherapy and have no sign of cancer progression.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Confirmed endometrial carcinoma that is newly diagnosed stage III or IV, or that has come back (recurrent). Stage III needs measurable disease left over after surgery, or disease that cannot be treated with debulking surgery. Recurrent disease needs no prior systemic cancer therapy, or a return more than 12 months after the last dose of earlier adjuvant treatment. No progression after first-line treatment.
- Earlier treatment
- Must have had 6 cycles of first-line platinum-based chemotherapy with pembrolizumab or dostarlimab (4 cycles of chemotherapy are allowed if it was stopped because of toxicity). Treatment in the trial must start 3 to 9 weeks after the last dose. Must not have had topoisomerase I inhibitors, B7-H4 targeted therapy, or an immune checkpoint inhibitor before (apart from the first-line therapy above).
- Biomarker or test result
- Tumor must be mismatch repair proficient (MMRp) or microsatellite stable (MSS). A tumor tissue sample is needed to test B7-H4, with the result before randomization.
Main reasons for not taking part
- Uterine sarcoma or neuroendocrine uterine cancer
- Current or past interstitial lung disease or non-infectious pneumonitis
- Another cancer that progressed or needed treatment within 36 months
- Serious side effects from earlier immunotherapy
- Active kidney condition, including needing dialysis
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF)
- Has received 6 cycles of first-line therapy (i.e. induction therapy), consisting of platinum-based doublet chemotherapy (e.g., carboplatin/paclitaxel) with immune checkpoint inhibition as part of standard of care (either pembrolizumab or dostarlimab) or via trial Run-In (dostarlimab). Receipt of only 4 cycles of chemotherapy is permitted if chemotherapy was discontinued due to toxicity, provided that the participant received at least 12 weeks of immune checkpoint inhibitor therapy during the induction period
- Is able to commence C1D1 of study treatment within 3 - 9 weeks of the final dose of first-line therapy
- Is deemed suitable to continue with maintenance therapy with immune checkpoint inhibition (dostarlimab or pembrolizumab)
- Demonstrates no clinical or radiographic progression of disease per investigator after the final dose of induction therapy. Final dose is defined as the last day that either platinum chemotherapy, taxane chemotherapy or immune checkpoint inhibition was given within the last cycle of induction therapy
- Has histologically confirmed endometrial carcinoma including but not limited to endometrioid, serous, clear cell and endometrial carcinosarcoma. Mixed epithelial carcinomas are permitted
- Meets one of the following criteria:; Has newly diagnosed stage III disease [2023 International Federation of Gynecology and Obstetrics (FIGO) staging] with measurable residual disease >1 cm after primary debulking surgery (incomplete cytoreduction); Has newly diagnosed stage III disease (2023 FIGO staging) that is not suitable for primary debulking surgery with measurable disease; Has newly diagnosed stage IV disease (2023 FIGO staging) and any residual disease status (measurable or non-measurable) following debulking surgery. Participants not suitable for primary debulking surgery are also permitted; Has recurrent disease and is naïve to systemic anticancer therapy and any disease status (measurable or non-measurable); Has recurrent disease after receiving prior neo-adjuvant/adjuvant systemic anticancer therapy and had a recurrence >12 months after last dose of neo-adjuvant/adjuvant treatment. Participants with any disease status (measurable or non-measurable) are permitted
- Has a tumor demonstrating either Mismatch Repair proficient (MMRp) or Microsatellite stable (MSS)
- Has provided a Formalin fixed, paraffin embedded (FFPE) tumor tissue sample sufficient for the central assessment of B7 homolog 4 protein (B7-H4) expression and MMR (if local MMRp/MSS test result(s) not available), with the result of B7-H4 expression testing available prior to date of randomization
- Is willing to use adequate contraception. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Who cannot take part
- Has a malignancy (except disease under study) that has progressed or required active treatment within 36 months prior to date of randomization except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas
- Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis
- Has experienced any of the following with prior immunotherapy: any imAE ≥ Grade 3, immune-mediated severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson syndrome [SJS], Toxic Epidermal Necrolysis [TEN], or Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS] syndrome, or myocarditis of any grade
- Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤ Grade 1 or to the baseline status preceding prior therapy, excluding alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy, or adverse reactions that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study
- Has had any major surgery within 28 days prior to date of C1D1 or received focal radiotherapy within 21 days prior to date of C1D1
- Has received treatment with an investigational agent within 30 days prior to C1D1
- Has received prior therapy with topoisomerase I inhibitors (e.g. irinotecan or topotecan) or Antibody-Drug Conjugate (ADC)with a topoisomerase I inhibitor warhead, B7-H4 targeted therapy, or immune checkpoint inhibitor
- Has received treatment with inhibitors of P-glycoprotein (P-gp) or Breast cancer resistant protein (BCRP), or OATP1B1/1B3 transporterswithin 7 days prior to the date of C1D1. Inducers of P-gp should be discontinued for at least 14 days prior to the date of C1D1
- Has a history of symptomatic pericarditis of any cause within 6 months prior to screening or evidence of cardiac abnormalities within 12 months prior to screening such as serious, uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities
- Mesenchymal tumors of the uterus (uterine sarcomas) and neuroendocrine uterine cancer
- Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Participants who exhibit these signs or symptoms as a result of the malignancy under investigation and whose conditions are deemed adequately controlled by the investigator may be eligible for inclusion
- Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety)
- Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Colony Stimulating Factor [G-CSF], Granulocyte-Macrophage Colony-Stimulating Factor [GM-CSF], or recombinant erythropoietin) within 14 days prior to C1D1
- Has an Alanine aminotransferase (ALT) value >2.5 × Upper limit of normal (ULN) or for participants with documented liver metastases/tumor infiltration has an ALT value >5 × ULN
- Has a total bilirubin value >1.5 × ULN
- Has Corrected QT interval (QTc) >470 milliseconds (msec)
Where in South Korea
Also in 2 other countries, 11 sites
- DaeguHospital not named in the registryContact: So-Jin Shin (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.
The 2 groups in the trial
- Mocertatug rezetecan plus physician's choice of immunotherapy (dostarlimab or pembrolizumab)Treatment being tested
Participants will receive Mocertatug rezetecan along with physician's choice of immunotherapy (Dostarlimab or Pembrolizumab)
Treatment: Mocertatug rezetecan, Dostarlimab, and Pembrolizumab
- Physician's choice of immunotherapy (dostarlimab or pembrolizumab)Existing treatment, for comparison
Participants will receive physician's choice of immunotherapy (Dostarlimab or Pembrolizumab alone)
Treatment: Dostarlimab and Pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer
- Plain-language title
- Mocertatug rezetecan plus immunotherapy as ongoing treatment for advanced or recurrent endometrial cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 3 November 2026